SCHEMBL5008719

SCHEMBL5008719

OCc1ccc(O)c(C(O)CN(CCCCCCOCCCCc2ccccc2)Cc2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 9/20 0.46
▸ ADRB1 P08588 4/20 0.46
▸ ADRB3 P13945 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ CHRM5 P08912 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ FPR3 P25089 1/20 0.46
▸ ADRA1D P25100 1/20 0.46
▸ HTR1D P28221 1/20 0.46
▸ HTR1B P28222 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14030608 0.83 ADRB2 (0.65) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL11021761 0.80 ADRB2 (0.45) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL29751132 0.78 ADRB2 (0.70) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL461364 0.78 ADRB2 (0.70) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL19422886 0.78 ADRB2 (0.48) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL5008664 0.78 ADRB2 (0.60) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL9864677 0.76 ADRB2 (0.67) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL10697205 0.76 ADRB2 (0.64) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL10477749 0.76 ADRB2 (0.46) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL10464526 0.75 ADRB2 (0.50) ADRB2ADRB1ADRB3KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937626-B1 Process and intermediates for the preparation of Salmeterol GENERICS UK LTD (GB) 2016-02-17 — — EP disclosed
US-8648214-B2 Processes suitable for the preparation of salmeterol GENERICS [UK] LIMITED (GB) 2014-02-11 — — US disclosed
EP-2641893-A1 PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS SALTS Generics [UK] Limited (GB) 2013-09-25 — — EP disclosed
US-20080262267-A1 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262267-A1 NOVEL PROCESS CYP4A11, HSD3B1, HSD11B1 ADRB2 128/4885ADRB1 53/4885ADRB3 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback